当前位置： SCI文献检索 > Indian Journal of Orthopaedics期刊下所有文献 > Zoledronic Acid Attenuates Early Bone Loss at Forearm in Patients with Acute Spinal Cord Injury.

Zoledronic Acid Attenuates Early Bone Loss at Forearm in Patients with Acute Spinal Cord Injury.

Abstract：

Study design:Randomized controlled trial. Objectives:To study the magnitude of bone loss at forearm in persons with acute spinal cord injury (SCI) & the effect of early administration of Zoledronic acid on its' prevention. Settings:Sawai Man Singh Medical College, Jaipur, India. Methods:Sixty patients with acute SCI were randomized either to receive standard medical and nursing care or Zoledronic acid infusion in combination with standard medical and nursing care. Areal bone mineral density (aBMD) was measured at the forearm (radius + ulna) once patients were medically stable using Dual Energy X-Ray Absorptiometry (DXA) at baseline and at 3, 6 and 12 months. Results:Significant differences in aBMD was found between the control & Zoledronic acid group at 1/3 forearm (- 0.064; 95% CI - 0.092 to - 0.036, p = 0.001), mid forearm (- 0.059; 95% CI - 0.084 to - 0.034, p = 0.001), UD forearm (- 0.048; 95% CI - 0.097 to 0.001, p = 0.016) and total forearm (- 0.048; 95% CI - 0.088 to - 0.008, p = 0.021) at 1 year in the paraplegic patients with SCI. Similar significant difference was also observed at 1/3 forearm (- 0.046; 95% CI - 0.073 to - 0.019, p = 0.002), mid forearm (- 0.063; 95% CI - 0.088 to - 0.037, p < 0.0001), UD forearm (- 0.084; 95% CI - 0.101 to - 0.067, p < 0.0001) and total forearm (- 0.115; 95% CI - 0.132 to - 0.097, p < 0.0001) respectively at 1 year in the quadriplegic patients with SCI. Significant differences in aBMD between the groups at 6 months post infusion was also observed at these sites in quadriplegic patients. [1/3 forearm - 0.022; 95% CI - 0.039 to - 0.005; p = 0.015, Mid forearm - 0.023; 95% CI - 0.042 to - 0.004; p = 0.019, UD forearm - 0.041; 95% CI - 0.055 to - 0.027; p < 0.0001 and Total forearm - 0.049; 95%CI - 0.062 to - 0.036; p < 0.0001]. Bone loss was reduced in the Zoledronic acid treated group compared to the standard treatment group in both paraplegic and quadriplegic patients. Conclusion:Single dose of 5mg intravenous Zoledronic acid is an effective treatment in preventing bone loss at the forearm for 12 months following acute spinal cord injury.

journal_name

Indian J Orthop

journal_title

Indian journal of orthopaedics

authors

Goenka S,Sethi S

doi

10.1007/s43465-020-00158-8

subject

Has Abstract

pub_date

2020-06-02 00:00:00

pages

127-133

issue

Suppl 1

eissn

0019-5413

issn

1998-3727

pii

158

journal_volume

pub_type

杂志文章

在线工具

Zoledronic Acid Attenuates Early Bone Loss at Forearm in Patients with Acute Spinal Cord Injury.